September 20, 2023 The First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint
September 14, 2023 Asieris’ New Drug APL-1401 Completes First Administration in Patient with Moderately to Severely Active UC
September 13, 2023 Asieris Announces Positive Interim Analysis Results in Phase II Clinical Trial of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer
August 29, 2023 Asieris Obtained IND Approval from NMPA for APL-1401, a Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
August 22, 2023 Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization
